The discussion highlights the growing role of real-world evidence in clinical trials, particularly as a potential substitute for control arms, while emphasizing the need to address biases associated with various control methods and advocating for a future dominated by platform trials that balance cost savings with reduced bias risks.

Berry Consultants has launched a series of informative videos and webinars on clinical trial topics, including disease progression modeling and innovative designs, available on the ICTR website, and invites readers to register for updates and share feedback.

This Podcast series by JAMA provides valuable interviews about the statistical and methodological foundations of clinical research.

On October 29, 2018, Berry Consultants launched a video series featuring Dr. Anna McGlothlin discussing the benefits and challenges of single arm clinical trials, particularly in rare diseases, while encouraging viewers to explore additional resources on the ICTR website.

In a public webinar on September 20, 2018, Berry Consultants' Kert Viele will explore the key components and trade-offs of gold standard randomized clinical trials versus innovative trial designs, discussing techniques such as flexible sample sizes and novel endpoints.

Berry Consultants will prominently participate in the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop in Washington, D.C. from September 12-14, 2018, with team members Scott Berry, Melanie Quintana, and Tom Parke presenting on various innovative topics related to clinical trial designs.